Midazolam Versus Dexamethasone-ondansetron in Preventing Postoperative Nausea-vomiting for Laparoscopic Surgeries
Primary Purpose
Postoperative Nausea and Vomiting
Status
Completed
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Normal saline, Midazolam
Dexamethasone, ondansetron
Sponsored by
About this trial
This is an interventional prevention trial for Postoperative Nausea and Vomiting focused on measuring Postoperative Nausea and Vomiting, Dexamethasone, Ondansetron, Midazolam, Laparoscopy, High risk
Eligibility Criteria
Inclusion Criteria:
- Patients more than 18 years of age
- Patients belonging to ASA-PS (American society of anesthesiologists Physical status) 1 or 2
- Patients with 2 or more risk factors for developing PONV undergoing laparoscopic surgeries
Exclusion Criteria:
- Anticipated difficult airway
- Obesity (body mass index >30 kg.m2),
- Pregnancy
- Patients with ASA - PS more than 2
- Consumption of an agent with anti-emetic properties within 24 h prior to commencement of the study.
- Known hypersensitivity to midazolam, ondansetron or dexamethasone
- Patients not giving consent.
- Patients with psychiatric illness or mental retardation
Sites / Locations
- Institute of Liver and Biliary Sciences
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Group A
Group B
Arm Description
Dexamethasone-ondansetron
Midazolam
Outcomes
Primary Outcome Measures
Postoperative nausea vomiting
the incidence of postoperative nausea and/or vomiting within first 24 hours postoperatively
Secondary Outcome Measures
Rescue antiemetic
The amount of antiemetic used within the first 24 hours.
Time to achieve PADSS>9
Time taken to achieve a Post anaesthesia discharge score of ≥9
Incidence of PON, POV, PONV at 2 hours and PON and POV at 24
Full Information
NCT ID
NCT03603119
First Posted
June 2, 2018
Last Updated
May 13, 2020
Sponsor
Institute of Liver and Biliary Sciences, India
1. Study Identification
Unique Protocol Identification Number
NCT03603119
Brief Title
Midazolam Versus Dexamethasone-ondansetron in Preventing Postoperative Nausea-vomiting for Laparoscopic Surgeries
Official Title
A Comparison of Midazolam Versus Dexamethasone-ondansetron in Preventing Postoperative Nausea-vomiting in High Risk Patients Undergoing Laparoscopic Surgeries
Study Type
Interventional
2. Study Status
Record Verification Date
May 2020
Overall Recruitment Status
Completed
Study Start Date
May 1, 2018 (Actual)
Primary Completion Date
November 15, 2019 (Actual)
Study Completion Date
November 15, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institute of Liver and Biliary Sciences, India
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Postoperative nausea and vomiting(PONV) affects 11 to 60 % of patients undergoing surgery and is a major cause of postoperative morbidity. Risk factors include female gender, non smokers, postoperative use of opioids and a past history of PONV. The simplified Apfel risk score is used to identify patients at risk for PONV. PONV prophylaxis is provided intraoperatively to patients with 2 or more risk factors. In spite of numerous drugs available, control of PONV remains a difficult task. Midazolam is a commonly used drug perioperatively for its anxiolytic and sedative properties. It decreases analgesic requirement and has also been found to have an antiemetic effect. This present study is designed to compare the prophylactic use of iv midazolam with a commonly used combination of dexamethasone-ondansetron in high risk patients (as defined by the modified Apfel score) undergoing laparoscopic surgeries.
Detailed Description
After Institutional Ethical Committee approval and written informed consent, 120 adult patients will be recruited for the study if they satisfy the inclusion and exclusion criteria as mentioned later. Consent will be obtained from the patients themselves. Standard protocol for administration of anaesthesia will be followed in all patients which is briefly described. All patients will receive general anaesthesia and will be induced with Propofol titrated to effect. Intraoperatively, isoflurane will be used as maintenance agent and vecuronium or atracurium as non depolarizing muscle relaxant. For analgesia, patients will receive intraoperative fentanyl.
For the purpose of the study, patients will be randomized into two groups depending upon a computer generated randomized sheet. Group A will receive 8mg of dexamethasone i.v. after anaesthesia induction and 4 mg of ondansetron i.v. 30 minutes prior to the end of surgery. Patients in Group B will be administered 2 mg of midazolam i.v. 30 minutes prior to the end of surgery. Time to achieve Post anaesthesia discharge score( PADSS) of ≥9 will be noted. Patients will be asked to report any incidence of nausea, retching or vomiting for the first 24 hours after surgery. The incidence of PONV and the amount of rescue antiemetic received will be noted at 2 hours and at 24 hours postoperatively. PONV will be scored based on the PONV Impact Scale score questionnaire (mentioned in the proforma)12. Rescue antiemetics will be administered in case the patient complains of PONV in accordance with American society of anesthesiologists (ASA) guidelines. The first line of rescue in Group A will be 10 mg of iv metaclopromide. Antihistaminics will be the second line of rescue antiemetic. In group B the first line of antiemetic will be 4 mg of ondansetron i.v. 10 mg of iv metaclopromide will be second line of rescue drug.
Study period : It is estimated that the study will be completed within one year Sample size Assuming a reduction in 45 % in the incidence of PONV, with α error of 0.05 and β of 0.02, we would require 60 patients in each group i.e. a total of 120 patients.13 Intervention: For administration of PONV prophylaxis, patients will be randomized into two groups depending upon a computer generated randomized sheet. Group A will receive 8mg of dexamethasone i.v. after anaesthesia induction and 4 mg of ondansetron i.v. 30 minutes prior to the end of surgery. Patients in Group B will be administered 2 mg of midazolam i.v. 30 minutes prior to the end of surgery.
Monitoring and assessment: Patients will be monitored 24 hours post operatively. Any complaints of nausea and/vomiting will be noted and rescue antiemetic will be administered as per the guidelines
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Nausea and Vomiting
Keywords
Postoperative Nausea and Vomiting, Dexamethasone, Ondansetron, Midazolam, Laparoscopy, High risk
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Care Provider
Masking Description
concealed envelopes
Allocation
Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group A
Arm Type
Active Comparator
Arm Description
Dexamethasone-ondansetron
Arm Title
Group B
Arm Type
Experimental
Arm Description
Midazolam
Intervention Type
Drug
Intervention Name(s)
Normal saline, Midazolam
Intervention Description
2 cc normal saline i.v. after anaesthesia induction.2 mg of injection midazolam intravenous 30 minutes prior to the end of surgery
Intervention Type
Drug
Intervention Name(s)
Dexamethasone, ondansetron
Intervention Description
8mg of dexamethasone i.v. after anaesthesia induction and 4 mg of ondansetron i.v. 30 minutes prior to the end of surgery.
Primary Outcome Measure Information:
Title
Postoperative nausea vomiting
Description
the incidence of postoperative nausea and/or vomiting within first 24 hours postoperatively
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Rescue antiemetic
Description
The amount of antiemetic used within the first 24 hours.
Time Frame
24 hours
Title
Time to achieve PADSS>9
Description
Time taken to achieve a Post anaesthesia discharge score of ≥9
Time Frame
1 hour
Title
Incidence of PON, POV, PONV at 2 hours and PON and POV at 24
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients more than 18 years of age
Patients belonging to ASA-PS (American society of anesthesiologists Physical status) 1 or 2
Patients with 2 or more risk factors for developing PONV undergoing laparoscopic surgeries
Exclusion Criteria:
Anticipated difficult airway
Obesity (body mass index >30 kg.m2),
Pregnancy
Patients with ASA - PS more than 2
Consumption of an agent with anti-emetic properties within 24 h prior to commencement of the study.
Known hypersensitivity to midazolam, ondansetron or dexamethasone
Patients not giving consent.
Patients with psychiatric illness or mental retardation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kelika Prakash, DM
Organizational Affiliation
Institute of Liver and Biliary Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institute of Liver and Biliary Sciences
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110070
Country
India
12. IPD Sharing Statement
Learn more about this trial
Midazolam Versus Dexamethasone-ondansetron in Preventing Postoperative Nausea-vomiting for Laparoscopic Surgeries
We'll reach out to this number within 24 hrs